These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25145365)

  • 1. Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
    Ghosh SK; Corkill MM; Hart HH; Ng KP
    N Z Med J; 2014 Aug; 127(1400):30-8. PubMed ID: 25145365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of scleroderma in a New Zealand tertiary rheumatology centre: emphasis on pulmonary complications.
    Ng K; Gow P
    N Z Med J; 2007 May; 120(1254):U2537. PubMed ID: 17515941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D; Humbert M; Hachulla E
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.
    Low AJ; Fowler D; Manghani MK; Young I; Garsia R; Torzillo P; Youssef P; Celermajer DS
    Intern Med J; 2013 Jan; 43(1):32-7. PubMed ID: 22032309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
    Mangat P; Conron M; Gabbay E; Proudman SM;
    Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.
    Morrisroe K; Stevens W; Sahhar J; Rabusa C; Nikpour M; Proudman S;
    Arthritis Res Ther; 2017 Mar; 19(1):42. PubMed ID: 28270192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors.
    Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Hawker GA; Feldman BM
    J Rheumatol; 2011 Mar; 38(3):462-9. PubMed ID: 21159827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).
    Wigley FM; Lima JA; Mayes M; McLain D; Chapin JL; Ward-Able C
    Arthritis Rheum; 2005 Jul; 52(7):2125-32. PubMed ID: 15986394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection and management of pulmonary arterial hypertension.
    Humbert M; Gerry Coghlan J; Khanna D
    Eur Respir Rev; 2012 Dec; 21(126):306-12. PubMed ID: 23204118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis.
    Quinlivan A; Thakkar V; Stevens W; Morrisroe K; Prior D; Rabusa C; Youssef P; Gabbay E; Roddy J; Walker JG; Zochling J; Sahhar J; Nash P; Lester S; Rischmueller M; Proudman SM; Nikpour M
    Intern Med J; 2015 Nov; 45(11):1134-40. PubMed ID: 26337683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
    Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
    Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.